Alzheimer's disease (AD) is the most common form of dementia and remains a growing worldwide health problem. As life expectancy continues to increase, the number of AD patients presenting for surgery and anesthesia will steadily rise. The etiology of sporadic AD is thought to be multifactorial, with environmental, biological and genetic factors interacting together to influence AD pathogenesis. Recent reports suggest that general anesthetics may be such a factor and may contribute to the development and exacerbation of this neurodegenerative disorder. Intra-neuronal neurofibrillary tangles (NFT), composed of hyperphosphorylated and aggregated tau protein are one of the main neuropathological hallmarks of AD. Tau pathology is important in AD as it correlates very well with cognitive dysfunction. Lately, several studies have begun to elucidate the mechanisms by which anesthetic exposure might affect the phosphorylation, aggregation and function of this microtubule-associated protein. Here, we specifically review the literature detailing the impact of anesthetic administration on aberrant tau hyperphosphorylation as well as the subsequent development of neurofibrillary pathology and degeneration.
Introduction
With a worldwide prevalence of 26.6 million cases as of 2006, Alzheimer's disease (AD) remains the most common form of dementia affecting the elderly population, and it is estimated that without a significant therapeutic breakthrough, the prevalence of this disorder will quadruple by the middle of this century (Brookmeyer et al., 2007) . Advancing age is considered the major risk factor for the development of sporadic AD, which constitutes the majority of AD cases (~99%) (Bufill et al., 2009; Harman, 2002) . AD pathology is considered to be multi-factorial, whereby a genetic predisposition interacts with environmental or biological factors, resulting in the development and/or acceleration of this neurodegenerative condition (Iqbal and Grundke-Iqbal, 2008; Papon et al., 2011) .
The two histopathological hallmarks of AD are extracellular amyloid plaques, which are composed mainly of beta-amyloid (Aβ) peptide, and intra-neuronal neurofibrillary tangles (NFT), which are primarily composed of aberrantly hyperphosphorylated tau protein assembled into paired helical filaments (Grundke-Iqbal et al., 1986) . Tau is normally enriched in the axonal compartment, but in AD and other tauopathies, it becomes hyperphosphorylated then subsequently relocalizes and aggregates in the somatodendritic compartment of affected neurons (Avila et al., 2004; Buee et al., 2000) .
Recent studies have demonstrated that anesthetics can have an impact on the neuropathogenesis of AD, and even possibly accelerate the clinical progression of this neurodegenerative disorder (Eckenhoff et al., 2004; Le Freche et al., 2012; Planel et al., 2009; Run et al., 2009; Tan et al., 2010; Tang et al., 2011a; Xie et al., 2006) . Furthermore, both pre-clinical and clinical studies have recently supported the notion that anesthesia has a significant impact on tau pathogenesis (Le Freche et al., 2012; Planel et al., 2007 Planel et al., , 2008 Planel et al., , 2009 Run et al., 2009 Run et al., , 2010 Tang et al., 2011a Tang et al., , 2011b Whittington et al., 2011) . In this article, we specifically review the literature on reported changes in tau pathology and function following anesthetic exposure in vivo, and provide tables summarizing the anesthetics used in these articles (Table 1) , as well as the results obtained from different groups (Table 2) .
Progress in Neuro-Psychopharmacology & Biological Psychiatry 47 (2013) 147-155
Abbreviations: 3R, 3-repeat tau isoforms; 4R, 4-repeat tau isoforms; 3×Tg-AD, triple transgenic Alzheimer's disease mouse model; AD, Alzheimer's disease; AKT/PKB, protein kinase B; APP, amyloid-β precursor protein; Aβ, amyloid-β; BDNF, brain-derived neurotrophic factor; CaMKII, calcium/calmodulin-dependent protein kinase II; cdk5, cyclin-dependent kinase 5; CSF, cerebrospinal fluid; Dex, dexmedetomidine; ERK, extracellular signal-regulated kinase; GABA, γ-aminobutyric acid; GSK-3β, glycogen synthase kinase-3β; i.p., intra peritoneal; JNK, c-Jun N-terminal kinase; MAC, minimum alveolar concentration; MAPK, mitogen-activated protein kinase; MT, microtubule; MWM, Morris water maze; NFT, neurofibrillary tangles; NMDA-R, N-methyl D-aspartate receptor; NR2B, subunit 2B of NMDA receptor; PP1, protein phosphatase 1; PP2A, protein phosphatase 2A; PP2B, protein phosphatase 2B; PS-1, presenilin-1; Ser, serine; Src, short for sarcoma, a non-receptor tyrosine kinase; Tau-SH-SY5Y cells, human neuroblastoma cells constitutively expressing human tau with 3 microtubule-binding domains; Thr, threonine.
